Annals of Oncology· @Annals_Oncology · X·· 1 day agoScore70
Body · original
📢 #ESMO26 concomitant paper - Atirmociclib and fulvestrant for patients with HR+/HER2– advanced/metastatic breast cancer who progressed on a prior cyclin-dependent kinase 4/6 inhibitor: primary analysis of the randomized FourLight-1 trial.
🔗https://tinyurl.com/449n4nu2
@hoperugo
101 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
1842Omatched by Proffered paper 2: Breast cancer, early and advanced stage
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.orgSource: Annals of Oncology · x.com